FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216352272> ?p ?o ?g. }

• W3216352272 endingPage "clincanres.3131.2021" @default.
• W3216352272 startingPage "clincanres.3131.2021" @default.
• W3216352272 abstract "Metastatic hormone receptor (HR)-positive, HER2-negative breast cancer is an important cause of cancer mortality. Endocrine treatment with or without additional targeted therapies has been the mainstay of treatment. This trial was designed to evaluate the combination of fulvestrant plus everolimus versus fulvestrant, everolimus, and anastrozole compared with fulvestrant alone in the first-line treatment of advanced HR-positive, HER2-negative breast cancer.This randomized placebo-controlled trial included postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had received no prior systemic therapy for metastatic disease. Participants were randomized to one of three treatment arms and the primary outcome was progression-free survival (PFS), comparing combinations of fulvestrant and everolimus with or without anastrozole with fulvestrant alone. Circulating tumor cells (CTC), as measured with two different methods, and circulating tumor DNA (ctDNA) were evaluated serially prior to treatment and the beginning of the second cycle of therapy.Due in part to changes in clinical practice, the study was closed after accruing only 37 participants. There was no evidence that everolimus-containing combination treatment improved PFS or overall survival relative to fulvestrant alone. When modeled continuously, an association was observed of baseline CTC and ctDNA with poorer survival.Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy-number variations in CTC was demonstrated." @default.
• W3216352272 created "2021-12-06" @default.
• W3216352272 creator A5000472988 @default.
• W3216352272 creator A5004756333 @default.
• W3216352272 creator A5008068115 @default.
• W3216352272 creator A5009523391 @default.
• W3216352272 creator A5018617106 @default.
• W3216352272 creator A5019170187 @default.
• W3216352272 creator A5023430660 @default.
• W3216352272 creator A5023917993 @default.
• W3216352272 creator A5025053302 @default.
• W3216352272 creator A5025364402 @default.
• W3216352272 creator A5034225982 @default.
• W3216352272 creator A5046583009 @default.
• W3216352272 creator A5057008789 @default.
• W3216352272 creator A5069748055 @default.
• W3216352272 creator A5073079380 @default.
• W3216352272 creator A5081380566 @default.
• W3216352272 creator A5081974715 @default.
• W3216352272 date "2021-11-29" @default.
• W3216352272 modified "2023-09-26" @default.
• W3216352272 title "A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222" @default.
• W3216352272 cites W2098152005 @default.
• W3216352272 cites W2105084636 @default.
• W3216352272 cites W2109561657 @default.
• W3216352272 cites W2111976640 @default.
• W3216352272 cites W2167188058 @default.
• W3216352272 cites W2552099557 @default.
• W3216352272 cites W2595794139 @default.
• W3216352272 cites W2620993107 @default.
• W3216352272 cites W2765435739 @default.
• W3216352272 cites W2774591115 @default.
• W3216352272 cites W2783029200 @default.
• W3216352272 cites W2790122515 @default.
• W3216352272 cites W2799435517 @default.
• W3216352272 cites W2802776309 @default.
• W3216352272 cites W2805575723 @default.
• W3216352272 cites W2925092419 @default.
• W3216352272 cites W2948069739 @default.
• W3216352272 cites W2976415870 @default.
• W3216352272 cites W3099860312 @default.
• W3216352272 cites W3169325545 @default.
• W3216352272 doi "https://doi.org/10.1158/1078-0432.ccr-21-3131" @default.
• W3216352272 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34844978" @default.
• W3216352272 hasPublicationYear "2021" @default.
• W3216352272 type Work @default.
• W3216352272 sameAs 3216352272 @default.
• W3216352272 citedByCount "0" @default.
• W3216352272 crossrefType "journal-article" @default.
• W3216352272 hasAuthorship W3216352272A5000472988 @default.
• W3216352272 hasAuthorship W3216352272A5004756333 @default.
• W3216352272 hasAuthorship W3216352272A5008068115 @default.
• W3216352272 hasAuthorship W3216352272A5009523391 @default.
• W3216352272 hasAuthorship W3216352272A5018617106 @default.
• W3216352272 hasAuthorship W3216352272A5019170187 @default.
• W3216352272 hasAuthorship W3216352272A5023430660 @default.
• W3216352272 hasAuthorship W3216352272A5023917993 @default.
• W3216352272 hasAuthorship W3216352272A5025053302 @default.
• W3216352272 hasAuthorship W3216352272A5025364402 @default.
• W3216352272 hasAuthorship W3216352272A5034225982 @default.
• W3216352272 hasAuthorship W3216352272A5046583009 @default.
• W3216352272 hasAuthorship W3216352272A5057008789 @default.
• W3216352272 hasAuthorship W3216352272A5069748055 @default.
• W3216352272 hasAuthorship W3216352272A5073079380 @default.
• W3216352272 hasAuthorship W3216352272A5081380566 @default.
• W3216352272 hasAuthorship W3216352272A5081974715 @default.
• W3216352272 hasBestOaLocation W32163522721 @default.
• W3216352272 hasConcept C121608353 @default.
• W3216352272 hasConcept C126322002 @default.
• W3216352272 hasConcept C143998085 @default.
• W3216352272 hasConcept C2775930923 @default.
• W3216352272 hasConcept C2776215463 @default.
• W3216352272 hasConcept C2777176818 @default.
• W3216352272 hasConcept C2778812593 @default.
• W3216352272 hasConcept C2779699572 @default.
• W3216352272 hasConcept C2780482068 @default.
• W3216352272 hasConcept C530470458 @default.
• W3216352272 hasConcept C71924100 @default.
• W3216352272 hasConceptScore W3216352272C121608353 @default.
• W3216352272 hasConceptScore W3216352272C126322002 @default.
• W3216352272 hasConceptScore W3216352272C143998085 @default.
• W3216352272 hasConceptScore W3216352272C2775930923 @default.
• W3216352272 hasConceptScore W3216352272C2776215463 @default.
• W3216352272 hasConceptScore W3216352272C2777176818 @default.
• W3216352272 hasConceptScore W3216352272C2778812593 @default.
• W3216352272 hasConceptScore W3216352272C2779699572 @default.
• W3216352272 hasConceptScore W3216352272C2780482068 @default.
• W3216352272 hasConceptScore W3216352272C530470458 @default.
• W3216352272 hasConceptScore W3216352272C71924100 @default.
• W3216352272 hasFunder F4320306260 @default.
• W3216352272 hasFunder F4320307770 @default.
• W3216352272 hasFunder F4320310388 @default.
• W3216352272 hasLocation W32163522721 @default.
• W3216352272 hasLocation W32163522722 @default.
• W3216352272 hasLocation W32163522723 @default.
• W3216352272 hasOpenAccess W3216352272 @default.
• W3216352272 hasPrimaryLocation W32163522721 @default.
• W3216352272 hasRelatedWork W2087683876 @default.

• next